Sarcoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: SRC014 MIFTS: 65	Sarcoma Categories: Bone diseases, Cancer diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Sarcoma

MalaCards integrated aliases for Sarcoma:

Name: Sarcoma ¹² ²⁹ ⁵⁴ ⁶ ¹⁵ ¹⁷ ⁷¹

Connective and Soft Tissue Neoplasm ¹²

Tumor of Soft Tissue and Skeleton ¹²

Sarcoma - Category ⁷¹

Sarcomas ¹⁵

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Bone diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Neoplasms

Malignant neoplasms of mesothelial and soft tissue

Malignant neoplasm of other connective and soft tissue

External Ids:

Disease Ontology ¹² DOID:1115

ICD9CM ³⁴ 171.9

ICD10 ³² C49

EFO ¹⁷ EFO_0000691

UMLS ⁷¹ C0153519 C1261473 C1299262

Sources

Summaries for Sarcoma

Disease Ontology : ¹² A cell type cancer that has material basis in abnormally proliferating cells derives from embryonic mesoderm.

MalaCards based summary : Sarcoma, also known as connective and soft tissue neoplasm, is related to ewing sarcoma and sarcoma, synovial. An important gene associated with Sarcoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Lopinavir and Lamivudine have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and myeloid, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : ⁷⁴ A sarcoma is a cancer that arises from transformed cells of mesenchymal (connective tissue) origin.... more...

Sources

Related Diseases for Sarcoma

Diseases related to Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2139)

#	Related Disease	Score	Top Affiliating Genes
1	ewing sarcoma	35.7	TP53 SSX1 KIT FLI1 EWSR1
2	sarcoma, synovial	35.6	SSX2 SSX1 KIT FLI1 EWSR1
3	heart sarcoma	35.1	SSX2 SSX1 KIT
4	retroperitoneal sarcoma	35.1	SSX2 KIT EWSR1
5	li-fraumeni syndrome	34.8	TP53 RB1 KRAS HRAS CHEK2
6	bone sarcoma	34.8	TP53 SSX2 SRC EWSR1
7	lung sarcoma	34.8	SSX2 SSX1 EWSR1
8	osteogenic sarcoma	34.7	TP53 RB1 JUN HOTAIR FAU CHEK2
9	epithelioid cell synovial sarcoma	34.7	SSX2 SSX1
10	ewing sarcoma of bone	34.6	FLI1 EWSR1
11	malignant fibrous histiocytoma	34.6	TP53 KIT EWSR1
12	spindle cell synovial sarcoma	34.5	SSX2 SSX1
13	periosteal osteogenic sarcoma	34.4	TP53 EWSR1
14	rhabdomyosarcoma	34.2	TP53 SSX2 SSX1 RB1 KRAS KIT
15	rhabdoid cancer	34.2	TP53 SSX2 EWSR1
16	uterine carcinosarcoma	34.2	TP53 RB1 PIK3CA KRAS KIT HRAS
17	fibrosarcoma	33.9	TP53 SSX2 SSX1 KIT JUN EWSR1
18	liposarcoma	33.8	TP53 RB1 PIK3CA JUN EWSR1
19	gastrointestinal stromal tumor	33.8	TP53 KRAS KIT HOTAIR BRAF
20	muscle cancer	33.7	TP53 SSX2 SSX1 KIT HRAS EWSR1
21	myxoid liposarcoma	33.7	TP53 SSX2 SSX1 EWSR1
22	embryonal rhabdomyosarcoma	33.7	TP53 KRAS HRAS EWSR1
23	myxofibrosarcoma	33.7	TP53 SSX2 KRAS KIT EWSR1 BACH1-IT2
24	angiosarcoma	33.7	TP53 KRAS KIT FLI1
25	carcinosarcoma	33.6	TP53 PIK3CA KRAS KIT HRAS
26	hemangiopericytoma, malignant	33.6	SSX2 SSX1 KIT
27	chondrosarcoma, extraskeletal myxoid	33.5	SSX2 SSX1 EWSR1
28	rhabdomyosarcoma 2	33.5	SSX2 SSX1 RB1 EWSR1
29	wilms tumor 1	33.5	TP53 KRAS KIT HRAS EWSR1 CHEK2
30	myeloid leukemia	32.7	TP53 LYN KRAS KIT HRAS FES
31	fibrous histiocytoma	32.6	TP53 KIT EWSR1
32	lymphoma	32.6	TP53 RB1 PIK3CA KIT CHEK2 BRAF
33	mesenchymal cell neoplasm	32.4	TP53 SSX2 KIT EWSR1
34	dedifferentiated liposarcoma	32.3	TP53 SSX2 SSX1 RB1 KIT EWSR1
35	adenocarcinoma	32.2	TP53 RB1 PIK3CA KRAS KIT HRAS
36	leukemia, acute myeloid	32.1	TP53 SRC PIK3CA LYN KRAS KIT
37	glioblastoma multiforme	32.1	TP53 SRC RB1 PIK3CA KRAS KIT
38	well-differentiated liposarcoma	32.1	TP53 SSX2 SSX1 KIT EWSR1
39	leukemia, acute lymphoblastic	32.0	TP53 RB1 LYN KRAS KIT JUN
40	hemangioma	32.0	TP53 KRAS KIT FLI1
41	leukemia	31.9	TP53 RB1 KRAS KIT HRAS HOTAIR
42	acute promyelocytic leukemia	31.9	TP53 SRC RB1 PIK3CA LYN KRAS
43	lymphangioma	31.9	TP53 PIK3CA KRAS HRAS
44	leukemia, chronic lymphocytic	31.9	TP53 SRC PIK3CA LYN KRAS KIT
45	connective tissue benign neoplasm	31.8	TP53 KIT EWSR1
46	adenoma	31.8	TP53 PIK3CA KRAS BRAF
47	neuroblastoma	31.8	TP53 SRC RB1 PIK3CA LYN KIT
48	exanthem	31.8	KRAS KIT HRAS
49	thyroid carcinoma	31.8	PIK3CA HRAS BRAF
50	thymoma	31.7	TP53 PIK3CA KIT HRAS

Graphical network of the top 20 diseases related to Sarcoma:

Sources

Symptoms & Phenotypes for Sarcoma

GenomeRNAi Phenotypes related to Sarcoma according to GeneCards Suite gene sharing:

²⁶ (show all 21)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-1	10.49	HRAS KRAS PIK3CA BRAF
2	Decreased viability	GR00055-A-2	10.49	HRAS KRAS PIK3CA BRAF
3	Decreased viability	GR00055-A-3	10.49	KRAS
4	Decreased viability	GR00106-A-0	10.49	KRAS
5	Decreased viability	GR00221-A-1	10.49	HRAS KRAS PIK3CA KIT
6	Decreased viability	GR00221-A-2	10.49	CHEK2 HRAS JUN KRAS PIK3CA
7	Decreased viability	GR00221-A-3	10.49	CHEK2 HRAS JUN
8	Decreased viability	GR00221-A-4	10.49	CHEK2 PIK3CA BRAF
9	Decreased viability	GR00249-S	10.49	JUN BRAF
10	Decreased viability	GR00301-A	10.49	KRAS BRAF KIT SRC
11	Decreased viability	GR00342-S-2	10.49	CHEK2
12	Decreased viability	GR00381-A-1	10.49	KRAS BRAF
13	Decreased viability	GR00386-A-1	10.49	JUN
14	Decreased viability	GR00402-S-2	10.49	PIK3CA
15	Decreased cell migration	GR00055-A-1	10	LYN FES
16	Decreased cell migration	GR00055-A-3	10	BRAF HRAS LYN PIK3CA
17	Decreased substrate adherent cell growth	GR00193-A-1	9.7	KIT
18	Decreased substrate adherent cell growth	GR00193-A-2	9.7	KIT
19	Decreased substrate adherent cell growth	GR00193-A-3	9.7	BRAF CHEK2
20	Decreased substrate adherent cell growth	GR00193-A-4	9.7	BRAF CHEK2 KIT
21	Decreased viability in CMK cells	GR00105-A-0	8.32	SRC

MGI Mouse Phenotypes related to Sarcoma:

⁴⁵ (show all 18)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	endocrine/exocrine gland	MP:0005379	10.31	BRAF CHEK2 FES FLI1 HRAS JUN
2	immune system	MP:0005387	10.29	BRAF CHEK2 FES FLI1 JUN KIT
3	cardiovascular system	MP:0005385	10.27	BRAF FES FLI1 HRAS JUN KIT
4	mortality/aging	MP:0010768	10.27	BRAF CHEK2 FES FLI1 HRAS JUN
5	hematopoietic system	MP:0005397	10.26	BRAF CHEK2 FES FLI1 JUN KIT
6	integument	MP:0010771	10.24	BRAF FES HRAS JUN KIT KRAS
7	craniofacial	MP:0005382	10.22	BRAF FES HRAS KIT KRAS LYN
8	embryo	MP:0005380	10.2	BRAF FLI1 JUN KIT KRAS PIK3CA
9	nervous system	MP:0003631	10.18	BRAF CHEK2 FES FLI1 HRAS JUN
10	digestive/alimentary	MP:0005381	10.16	BRAF FES HRAS KIT KRAS LYN
11	neoplasm	MP:0002006	10.14	BRAF CHEK2 FES FLI1 HRAS KIT
12	liver/biliary system	MP:0005370	10.13	BRAF FES FLI1 JUN KIT KRAS
13	muscle	MP:0005369	10.03	BRAF FES FLI1 KIT KRAS PIK3CA
14	no phenotypic analysis	MP:0003012	9.87	HRAS JUN KIT KRAS PIK3CA RB1
15	respiratory system	MP:0005388	9.81	BRAF HRAS JUN KIT KRAS LYN
16	pigmentation	MP:0001186	9.73	BRAF KIT KRAS RB1 SRC TP53
17	skeleton	MP:0005390	9.7	BRAF FES HRAS JUN KIT KRAS
18	vision/eye	MP:0005391	9.28	BRAF FES JUN KIT KRAS PIK3CA

Sources

Drugs & Therapeutics for Sarcoma

Drugs for Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 592)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Lopinavir

Approved

Phase 4

192725-17-0

92727

Lamivudine

Approved, Investigational

Phase 4

134678-17-4

60825

Stavudine

Approved, Investigational

Phase 4

3056-17-5

18283

Aprepitant

Approved, Investigational

Phase 4

170729-80-3

6918365 151165

Tranexamic Acid

Approved

Phase 4

1197-18-8

5526

Tinzaparin

Approved

Phase 4

9041-08-1, 9005-49-6

25244225

Dalteparin

Approved

Phase 4

9005-49-6

Cytochrome P-450 CYP3A Inhibitors

Phase 4

Hemostatics

Phase 4

Antifibrinolytic Agents

Phase 4

Coagulants

Phase 4

Heparin, Low-Molecular-Weight

Phase 4

Morphine

Approved, Investigational

Phase 3

57-27-2

5288826

Meloxicam

Approved, Vet_approved

Phase 3

71125-38-7

54677470 5281106

Irinotecan

Approved, Investigational

Phase 3

97682-44-5, 100286-90-6

60838

Dactinomycin

Approved, Investigational

Phase 3

50-76-0

457193 2019

Aldesleukin

Approved

Phase 3

85898-30-2, 110942-02-4

Nicotine

Approved

Phase 3

54-11-5

942 89594

Darbepoetin alfa

Approved, Investigational

Phase 3

11096-26-7, 209810-58-2

Abacavir

Approved, Investigational

Phase 2, Phase 3

136470-78-5

441300 65140

Levoleucovorin

Approved, Investigational

Phase 3

68538-85-2

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 3

437-38-7

3345

Sulfamethoxazole

Approved

Phase 3

723-46-6

5329

Trimethoprim

Approved, Vet_approved

Phase 3

738-70-5

5578

Amphotericin B

Approved, Investigational

Phase 3

1397-89-3

5280965 14956

Fluconazole

Approved, Investigational

Phase 3

86386-73-4

3365

Thioguanine

Approved

Phase 3

154-42-7

2723601

Varenicline

Approved, Investigational

Phase 3

249296-44-4

5310966

Olaparib

Approved

Phase 3

763113-22-0

23725625

Palbociclib

Approved, Investigational

Phase 3

571190-30-2

5005498 11431660 5330286

Epirubicin

Approved

Phase 3

56420-45-2

41867

Ceritinib

Approved

Phase 3

1032900-25-6

Denosumab

Approved

Phase 3

615258-40-7

Mechlorethamine

Approved, Investigational

Phase 3

51-75-2

4033

Sorafenib

Approved, Investigational

Phase 3

284461-73-0

216239 406563

Carboplatin

Approved

Phase 3

41575-94-4

10339178 38904 498142

Paclitaxel

Approved, Vet_approved

Phase 3

33069-62-4

36314

Cetuximab

Approved

Phase 3

205923-56-4

56842117 2333

Vincristine

Approved, Investigational

Phase 3

57-22-7, 2068-78-2

5978

Daunorubicin

Approved

Phase 3

20830-81-3

30323

Bortezomib

Approved, Investigational

Phase 3

179324-69-7

387447 93860

Zoledronic Acid

Approved

Phase 3

118072-93-8

68740

Mitoxantrone

Approved, Investigational

Phase 3

65271-80-9

4212

Idarubicin

Approved

Phase 3

58957-92-9

42890

Bleomycin

Approved, Investigational

Phase 3

11056-06-7

5360373

Methotrexate

Approved

Phase 3

59-05-2, 1959-05-2

126941

Cefazolin

Approved

Phase 3

25953-19-9

656510 33255

Cytarabine

Approved, Experimental, Investigational

Phase 3

147-94-4, 65-46-3

6253

Emtricitabine

Approved, Investigational

Phase 3

143491-57-0

60877

Efavirenz

Approved, Investigational

Phase 3

154598-52-4

64139

Interventional clinical trials:

(show top 50) (show all 1861)

#	Name	Status	NCT ID	Phase	Drugs
1	EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children	Unknown status	NCT00339118	Phase 4	doxorubicin, cytoxan
2	GCSF Plus Plerixafor as First-line Treatment for Autologous Stem Cells Harvest in Children With Malignant Diseases in Need for High-dose Chemotherapy With Stem Cell Rescue.	Unknown status	NCT02006225	Phase 4	Plerixafor
3	Optimizing Influenza Vaccination in Surgical Oncology Patients	Unknown status	NCT01698177	Phase 4
4	A Randomized Comparison of Protease Inhibitor-based Versus Non-nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy for Initial Treatment of Individuals With AIDS-related Kaposi's Sarcoma in Sub-Saharan Africa	Completed	NCT00444379	Phase 4	Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
5	Phase IV Trial to Use Stereotactic Body Radiotherapy for Head and Neck Tumors	Completed	NCT01344356	Phase 4
6	A Prospective Randomized Trial Comparing the Response of HIV Kaposi's Sarcoma (KS) to HAART Versus the Combination of HAART and Chemotherapy (CXT)	Completed	NCT00380770	Phase 4	Generic HAART Triomune : d4T, 3TC, NVP;Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
7	Prospective, Randomized Evaluation of Hyperbaric Oxygen Therapy on Wound Healing Following Management of Soft Tissue Sarcoma With Neo-Adjuvant Radiation and Surgical Resection	Recruiting	NCT03144206	Phase 4	Hyperbaric oxygen
8	Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule	Recruiting	NCT04223583	Phase 4	Anlotinib Hydrochloride
9	Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction: A Randomized Controlled Trial	Recruiting	NCT04347122	Phase 4	Tranexamic Acid (TXA)
10	Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma	Recruiting	NCT03514381	Phase 4	Patients starting a treatment with Doxorubicin and Ifosfamide
11	Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib — a Randomized, Controlled Trial	Recruiting	NCT03735758	Phase 4	pazopanib or guideline conform chemotherapy
12	Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma: a Single Arm Prospective Study	Recruiting	NCT04056962	Phase 4	Tacrolimus ointment
13	An Open Label, Multicenter, Non-Comparative, Phase IV Study of Panitumumab to Characterize Its Safety, Tolerability and Activity in Indian Subjects With Previously Treated Wild-Type RAS (KRAS and NRAS), Metastatic Colorectal Cancer	Recruiting	NCT02301962	Phase 4	Panitumumab
14	Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma:A Prospective, Randomized Open Trial	Recruiting	NCT04077515	Phase 4	Sirolimus(0.8mg/m2);Sirolimus(0.7mg/m2)
15	Low Molecular Weight Heparin Versus Aspirin for Venous Thromboembolism Prophylaxis in Orthopaedic Oncology	Enrolling by invitation	NCT03244020	Phase 4	Aspirin 325mg;Enoxaparin 40Mg/0.4mL Prefilled Syringe
16	Registry of Retroperitoneal, Abdominal, Pelvic and Truncal Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet® to Evaluate the Safety and Feasibility Over 5 Years	Not yet recruiting	NCT04033081	Phase 4
17	Phase III Study About the Effects of the Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas	Unknown status	NCT00162721	Phase 3	doxorubicin, ifosfamide, cisplatin
18	Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas	Unknown status	NCT00334854	Phase 3	doxorubicin hydrochloride;ifosfamide
19	Phase III Study of The Role of Barrier Resection in Local Control in Treatment of Extremity Soft Tissue Sarcomas	Unknown status	NCT02120768	Phase 3
20	A Registered Randomized, Double-Blind, Placebo-Controlled (2:1), Multi-Centered Clinical Trial of Anlotinib as a Treatment for Soft Tissue Sarcoma	Unknown status	NCT02449343	Phase 2, Phase 3	Anlotinib;Placebo
21	Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age	Unknown status	NCT00346164	Phase 3	doxorubicin hydrochloride;ifosfamide
22	Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Adriamycin, Bleomycin, and Vincristine (ABV) in the Treatment of Severe AIDS-Related Kaposi's Sarcoma	Unknown status	NCT00002318	Phase 3	Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
23	A Phase III Randomized Study of Preoperative Radiotherapy Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcoma (RPS)	Unknown status	NCT01344018	Phase 3
24	MULTICENTER RANDOMIZED, OPEN-LABEL PHASE II/III STUDY, TO COMPARE EFFICACY OF NBTXR3 IMPLANTED AS INTRATUMOR INJECTION AND ACTIVATED BY RADIOTHERAPY, VERSUS RADIOTHERAPY ALONE IN PATIENTS WITH LOCALLY ADVANCED SOFT TISSUE SARCOMA (EXTREMITY AND TRUNK WALL)	Unknown status	NCT02379845	Phase 2, Phase 3
25	EUROPEAN INTERGROUP COOPERATIVE EWING'S SARCOMA STUDY [EICESS 92]	Unknown status	NCT00002516	Phase 3	cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
26	Intensified Methotrexate, Vinblastine, Doxorubicin and Cisplatin +/-Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma in Patients Without Harvey Nor Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations. Phase II Study	Unknown status	NCT02818725	Phase 3	Chemotherapy;panitumumab
27	European Ewing Tumour Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G.99)	Unknown status	NCT00020566	Phase 3	busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
28	Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II)	Unknown status	NCT01087268	Phase 3
29	A Double-Blind Randomized Placebo Controlled Trial for Prevention of Tuberculosis-Immune Reconstitution Inflammatory Syndrome With Non-Steroid Anti-Inflammatory Drugs (NSAIDs) in HIV-Infected Adults	Unknown status	NCT02060006	Phase 3	Meloxicam 7.5mg daily for 8 weeks
30	A Protocol For Nonmetastatic Rhabdomyosarcoma [RMS-2005]	Unknown status	NCT00379457	Phase 3	carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate;vinorelbine tartrate
31	Prospective and Randomized Study of Fixed Versus Flexible Prophylactic Administration of Granulocyte Colony-Stimulating Factor (G-CSF) in Children With Cancer	Unknown status	NCT01987596	Phase 3
32	Comparing the Effectiveness of Combined Hyperthermia and External Beam Radiation (EBRT) Versus EBRT Alone in Treating Patients With Painful Bone Metastases	Unknown status	NCT01842048	Phase 3
33	Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine and Irinotecan (VI) for Patients With Intermediate-Risk Rhabdomyosarcoma (RMS)	Unknown status	NCT00354835	Phase 3	Irinotecan Hydrochloride;Cyclophosphamide;Vincristine Sulfate
34	A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator's Choice in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy	Completed	NCT02049905	Phase 3	Aldoxorubicin;Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
35	Ph III Random Trial of 120-Min Infusion Gemcitabine v. 90-Min Infusion Gemcitabine + Docetaxel in Unresectable Soft Tissue Sarcoma: A Multi-Disciplinary Trial of the North Amer. Sarcoma Study Group of the Connective Tissue Oncology Society	Completed	NCT00142571	Phase 3	Gemcitabine;Docetaxel
36	A Pivotal Trial to Determine the Efficacy and Safety of AP23573 When Administered as Maintenance Therapy to Patients With Metastatic Soft-Tissue or Bone Sarcomas	Completed	NCT00538239	Phase 3	ridaforolimus;Placebo
37	A Phase III Randomized Study of Preoperative Radiation Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcomas (RPS)	Completed	NCT00091351	Phase 3
38	Randomized Study Comparing Neoadjuvant Chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) Combined With Regional Hyperthermia (RHT) Versus Neoadjuvant Chemotherapy Alone in the Treatment of High-Risk Soft Tissue Sarcomas in Adults	Completed	NCT00003052	Phase 3	doxorubicin hydrochloride;etoposide;ifosfamide
39	A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination With Doxorubicin vs. Doxorubicin Alone in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma	Completed	NCT01440088	Phase 3	TH-302 in Combination with Doxorubicin;Doxorubicin
40	A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis) Versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients With Translocation-Related Sarcomas (TRS)	Completed	NCT00796120	Phase 3	Trabectedin;Doxorubicin;Ifosfamide
41	Phase 3, Open Label, Multi-centre, Randomised Controlled International Study in Ewing Sarcoma	Completed	NCT00987636	Phase 3	Zoledronic acid;Busulfan;Treosulfan
42	A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy	Completed	NCT00753688	Phase 3	PAZOPANIB;Placebo
43	A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.	Completed	NCT00002093	Phase 3	Daunorubicin (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
44	Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.	Completed	NCT00002147	Phase 3	Doxorubicin hydrochloride (liposomal)
45	MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood	Completed	NCT00002898	Phase 3	carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
46	Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia Administered to Patients With High-Risk Sarcoma Receiving Intensive Chemotherapy (Adriamycin and Ifosfamide (AI))	Completed	NCT00038311	Phase 3	PN-152,243)/PN-196,444
47	Double-Blind Randomized Evaluation of Clinical Benefits of DOXIL in Patients With AIDS-Related Kaposi's Sarcoma Treated With DOXIL or DaunoXome	Completed	NCT00002985	Phase 3	daunorubicin hydrochloride;pegylated liposomal doxorubicin hydrochloride
48	Open Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma	Completed	NCT00002319	Phase 3	Doxorubicin hydrochloride (liposomal)
49	Randomised Trial of Post-Operative Radiotherapy Given to Adult Patients With Extremity Soft Tissue Sarcoma [VORTEX]	Completed	NCT00423618	Phase 3
50	METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP)	Completed	NCT00002764	Phase 3	doxorubicin hydrochloride;ifosfamide

Search NIH Clinical Center for Sarcoma

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Ifosfamide

Mitoxantrone

Mitoxantrone Hydrochloride

Thiotepa

Sources

Genetic Tests for Sarcoma

Genetic tests related to Sarcoma:

#	Genetic test	Affiliating Genes
1	Sarcoma ²⁹

Sources

Anatomical Context for Sarcoma

MalaCards organs/tissues related to Sarcoma:

⁴⁰

Bone, Lung, Myeloid, Breast, Liver, Kidney, Uterus

Sources

Publications for Sarcoma

Articles related to Sarcoma:

(show top 50) (show all 30590)

#	Title	Authors	PMID	Year
1	Sarcoma of the cervical spine after radiation treatment for thyroid cancer. ⁵⁴ ⁶¹	Hu CK...Tu YK	20375775	2010
2	IGF-1R targeted treatment of sarcoma. ⁵⁴ ⁶¹	Toretsky JA...Gorlick R	20036195	2010
3	[A case of undifferentiated (embryonal) liver sarcoma mimicking klatskin tumor in an adult]. ⁶¹ ⁵⁴	Lee JA...Kim HJ	20168062	2010
4	Claudin-1 is expressed in perineurioma-like low-grade fibromyxoid sarcoma. ⁶¹ ⁵⁴	Thway K...Calonje E	19540561	2009
5	Undifferentiated sarcoma: does it exist? A clinicopathologic study of 7 pediatric cases and review of literature. ⁵⁴ ⁶¹	Alaggio R...Coffin CM	19647855	2009
6	Prognostic significance of phosphorylated FOXO1 expression in soft tissue sarcoma. ⁵⁴ ⁶¹	Zhang B...Aozasa K	19408047	2009
7	[A sarcoma of the colonic wall with desmin expression]. ⁶¹ ⁵⁴	Lavoine E...Bertrand G	19364593	2009
8	Low-grade fibromyxoid sarcoma versus fibromatosis: a comparative study of clinicopathological and immunohistochemical features. ⁵⁴ ⁶¹	Meng GZ...Geng JG	19021197	2009
9	Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma. ⁶¹ ⁵⁴	Friedrichs N...Hartmann W	18855347	2008
10	Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma. ⁵⁴ ⁶¹	Rouleau C...Teicher BA	19010839	2008
11	New targets for therapy of sarcoma. ⁵⁴ ⁶¹	Magenau JM...Schuetze SM	18525335	2008
12	Leukemic transformation of Langerhans cell sarcoma. ⁶¹ ⁵⁴	Sumida K...Gondo H	18360746	2008
13	Stathmin activity influences sarcoma cell shape, motility, and metastatic potential. ⁵⁴ ⁶¹	Belletti B...Baldassarre G	18305103	2008
14	[Diffuse expression of KIT in a pulmonary artery sarcoma]. ⁵⁴ ⁶¹	Kagioka H...Fukui M	18516991	2008
15	Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry. ⁶¹ ⁵⁴	Kushitani K...Inai K	18199156	2008
16	Immunohistochemical discrimination between the ASPL-TFE3 fusion proteins of alveolar soft part sarcoma. ⁶¹ ⁵⁴	Vistica DT...Shoemaker RH	18176180	2008
17	Pulmonary artery sarcoma mimicking a pulmonary embolism. ⁵⁴ ⁶¹	Sandhu A...Kuriakose P	18453737	2008
18	Ewing sarcoma protein ewsr1 maintains mitotic integrity and proneural cell survival in the zebrafish embryo. ⁶¹ ⁵⁴	Azuma M...Hickstein DD	17912356	2007
19	Standards and novel therapeutic options in the treatment of patients with soft tissue sarcoma. ⁵⁴ ⁶¹	Kasper B	18474006	2007
20	Expression of MYCN in pediatric synovial sarcoma. ⁵⁴ ⁶¹	Somers GR...Thorner PS	17464317	2007
21	High prevalence of p53 exon 4 mutations in soft tissue sarcoma. ⁶¹ ⁵⁴	Das P...Lev D	17429838	2007
22	Immunostaining for SYT protein discriminates synovial sarcoma from other soft tissue tumors: analysis of 146 cases. ⁶¹ ⁵⁴	He R...Baila H	17334346	2007
23	Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines. ⁵⁴ ⁶¹	Hartmann JT	17264755	2007
24	Markers of angiogenesis and clinical features in patients with sarcoma. ⁵⁴ ⁶¹	DuBois S...Demetri G	17265525	2007
25	Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families. ⁵⁴ ⁶¹	Manoukian S...Della-Torre G	17224268	2007
26	Mediastinal follicular dendritic cell sarcoma involving bone marrow: a case report and review of the literature. ⁶¹ ⁵⁴	Jiang L...Bueso-Ramos CE	17126255	2006
27	Apoptosis induced by chemotherapeutic agents involves c-Jun N-terminal kinase activation in sarcoma cell lines. ⁶¹ ⁵⁴	Koyama T...Mizuguchi J	16705697	2006
28	Immunohistochemical analysis of embryonal sarcoma of the liver. ⁵⁴ ⁶¹	Kiani B...Frankel WL	16785789	2006
29	Prognostic significance of Wilms tumor gene (WT1) mRNA expression in soft tissue sarcoma. ⁵⁴ ⁶¹	Sotobori T...Yoshikawa H	16607650	2006
30	Mammary NOS-type sarcoma with CD10 expression: a rare entity with features of myoepithelial differentiation. ⁵⁴ ⁶¹	Leibl S...Moinfar F	16625090	2006
31	Pulmonary manifestation of a Langerhans cell sarcoma: case report and review of the literature. ⁵⁴ ⁶¹	Julg BD...Mayr D	16328350	2006
32	The role of genetic testing in soft tissue sarcoma. ⁶¹ ⁵⁴	Antonescu CR	16359533	2006
33	Autoantibody production from a thymoma and a follicular dendritic cell sarcoma associated with paraneoplastic pemphigus. ⁶¹ ⁵⁴	Wang J...Zhu XJ	16120143	2005
34	Genetic predictors for drug resistance in soft tissue sarcoma: a review of publications in 2004. ⁶¹ ⁵⁴	Fayette J...Blay JY	15933471	2005
35	Efficacy of Wnt-1 monoclonal antibody in sarcoma cells. ⁶¹ ⁵⁴	Mikami I...Jablons DM	15913453	2005
36	Prognostic importance of vascular endothelial growth factor and its receptors in the uterine sarcoma. ⁵⁴ ⁶¹	Arita S...Nomura S	15823121	2005
37	Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma. ⁶¹ ⁵⁴	Hartmann JT...Patel S	15631540	2005
38	p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. ⁶¹ ⁵⁴	Baldassarre G...Colombatti A	15652749	2005
39	Intimal sarcoma of the pulmonary artery: report of an autopsy case. ⁶¹ ⁵⁴	Miura S...Sekine I	16136754	2005
40	Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma. ⁶¹ ⁵⁴	Maseide K...Hill RP	15240538	2004
41	A modified p53 enhances apoptosis in sarcoma cell lines mediated by doxorubicin. ⁶¹ ⁵⁴	Tang HJ...Lin J	15026814	2004
42	Familial sarcoma: challenging pedigrees. ⁶¹ ⁵⁴	Lynch HT...Gatalica Z	14584079	2003
43	Sarcoma and familial retinoblastoma. ⁶¹ ⁵⁴	Chen CS...Muecke J	14516425	2003
44	Fusion of the FUS and BBF2H7 genes in low grade fibromyxoid sarcoma. ⁶¹ ⁵⁴	Storlazzi CT...Panagopoulos I	12915480	2003
45	Carcinosarcoma (pure endocrine cell carcinoma with sarcoma components) of the stomach. ⁵⁴ ⁶¹	Teramachi K...Ochiai A	12895235	2003
46	Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling. ⁶¹ ⁵⁴	Segal NH...Houghton AN	12721254	2003
47	Reduced expression of hMSH2 protein is correlated to poor survival for soft tissue sarcoma patients. ⁶¹ ⁵⁴	Taubert HW...Wurl P	12712483	2003
48	Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. ⁶¹ ⁵⁴	Hwang SJ...Strong LC	12610779	2003
49	fau and its ubiquitin-like domain (FUBI) transforms human osteogenic sarcoma (HOS) cells to anchorage-independence. ⁶¹ ⁵⁴	Rossman TG...Komissarova EV	12660817	2003
50	Immunomic analysis of human sarcoma. ⁶¹ ⁵⁴	Lee SY...Scanlan MJ	12601173	2003

Sources

Genes for Sarcoma

Genes related to Sarcoma (3 elite genes):

(show top 50) (show all 148)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	TP53	Tumor Protein P53	Protein Coding	451.88	Pathogenic ⁶ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Disorders Publications Pathways & Interactions Variants (show sections)	8821948 17136003 9140310 (more) 15618970 8649865 17369843 11800644 14739938 8272291 8133539 2216456 8260365 8630896 1333524 8076351 11496306 9600120 12002339 11401317 8797875 8387391 11341347 9739384 9645763 17536310 15026814 10475130 9057590 1565143 12610779 9071998 7640047 8064888 8425179 1423262 10910082 17224268 7617655 8797580 11422494 11958662 8834522 19114327 8306343 12620916 10412269 10347252 9626480 9568075 9006316 17251932 16492679 10942797 8174045 17572079 16857722 12574910 10766348 10606188 9820864 9717829 8186161 11291094 9528860 9341900 8552572 10395173 8878024 7981072 17643097 11571738 11463499 11059649 8630877 17429838 11745235 1933904 10357774 2143022 1614537 9504819 7839308 8382897 1731521 2253237 19096301 18677381 18521237 17287860 15933471 18855997 12406399 10424735 10591653 9458358 9269965 8673929 8666894 16785789
2	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	438.09	Pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Publications Proteins Pathways & Interactions Variants (show sections)
3	CHEK2	Checkpoint Kinase 2	Protein Coding	433.74	Pathogenic ⁶ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Disorders Publications Variants (show sections)	11746983
4	HOTAIR	HOX Transcript Antisense RNA	RNA Gene	155.52	Experimental evidence: Regulation ³⁸ DISEASES inferred ¹⁵	23543869
5	LINC00680	Long Intergenic Non-Protein Coding RNA 680	RNA Gene	154.45	Experimental evidence: Association ³⁸ DISEASES inferred ¹⁵	29113307
6	BACH1-IT2	BACH1 Intronic Transcript 2	RNA Gene	154.12	Experimental evidence: Association ³⁸ DISEASES inferred ¹⁵	29113307
7	SSX2	SSX Family Member 2	Protein Coding	60.4	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Disorders Publications Gene name Summaries Functions (show sections)	10398111 12601173 9788446 (more) 12469233
8	SSX1	SSX Family Member 1	Protein Coding	59.45	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Disorders Publications Gene name Summaries Functions (show sections)	10399965 12469233
9	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	59.14	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications Gene name Summaries Functions Domains & Families (show sections)	12912938 11865845 15015617 (more) 18516991 16306788 12219791 16082245 18076015 20490332 16135486 20081808 18753943 18525335 16767900 15631540 15289315 17264755 10509034 16785789 16359533 17193824 19664491 20189232 14657591
10	SRC	SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase	Protein Coding	58.14	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Gene name Summaries Pathways & Interactions Functions Domains & Families (show sections)
11	EWSR1	EWS RNA Binding Protein 1	Protein Coding	54.88	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Disorders Publications Gene name Summaries (show sections)	18162764 18580682 17912356 (more) 8834175 7708500 7493135 9781944 9060841 16730884 15183454 11896622 9306965 7623847 7539287 9160316 19837262 18620564 10842247 12881716 11015571 12721254 10602519 8890175 8187063
12	FES	FES Proto-Oncogene, Tyrosine Kinase	Protein Coding	51.1	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications Gene name Summaries Functions Domains & Families (show sections)	7696187 17588535
13	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	48.86	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Gene name Summaries Pathways & Interactions Functions (show sections)
14	FLI1	Fli-1 Proto-Oncogene, ETS Transcription Factor	Protein Coding	48.32	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Disorders Publications Gene name Summaries (show sections)	11474291 8336942
15	JUN	Jun Proto-Oncogene, AP-1 Transcription Factor Subunit	Protein Coding	47.8	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Gene name Summaries Pathways & Interactions Functions (show sections)
16	RB1	RB Transcriptional Corepressor 1	Protein Coding	45.62	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Disorders Publications Summaries Pathways & Interactions (show sections)	17369843 9269824 1988704 (more) 2233918 8781571 1381957 12210086 14516425 1683797 1888791 2216456 12924447 2217208 17122635 1862090 8418305 11452937
17	LYN	LYN Proto-Oncogene, Src Family Tyrosine Kinase	Protein Coding	45.36	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Gene name Pathways & Interactions Functions Domains & Families (show sections)
18	FAU	FAU Ubiquitin Like And Ribosomal Protein S30 Fusion	Protein Coding	45.03	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications Gene name Summaries Functions (show sections)	1326960 8395683 7642109 (more) 7774934 12660817 8406491 7512365 19671159
19	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	43.74	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications Gene name Pathways & Interactions Variants (show sections)	19096301 17636402 19270482 (more) 19376842 20336783 16916990 19170230 19451690 19912113 18824008
20	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	43.73	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications Gene name Functions Domains & Families (show sections)	19955937 17570501 18628356 (more) 19179424 16098042 17119447 17210745 18368129 19658182 18753363 14691295 18957483 17942568 19127559 19578554
21	PDGFB	Platelet Derived Growth Factor Subunit B	Protein Coding	42.59	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications Gene name Pathways & Interactions Functions (show sections)	7903911 20194851 2016272 (more) 9562384
22	SS18	SS18 Subunit Of BAF Chromatin Remodeling Complex	Protein Coding	42.08	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Disorders Publications Gene name (show sections)	17334346 15905690 12469233
23	SSX4	SSX Family Member 4	Protein Coding	39.67	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Gene name Summaries Functions (show sections)
24	ASPSCR1	ASPSCR1 Tether For SLC2A4, UBX Domain Containing	Protein Coding	39.12	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Gene name Summaries (show sections)
25	ERG	ETS Transcription Factor ERG	Protein Coding	38.52	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries Functions (show sections)
26	CREB3L2	CAMP Responsive Element Binding Protein 3 Like 2	Protein Coding	38.09	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Disorders Publications Summaries (show sections)	17117415 12915480
27	PATZ1	POZ/BTB And AT Hook Containing Zinc Finger 1	Protein Coding	38	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Gene name Summaries (show sections)
28	YES1	YES Proto-Oncogene 1, Src Family Tyrosine Kinase	Protein Coding	37.91	DISEASES inferred ¹⁵ GeneCards inferred via : Gene name Summaries Functions Domains & Families (show sections)
29	CDK4	Cyclin Dependent Kinase 4	Protein Coding	37.18	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications Pathways & Interactions Variants (show sections)	16160477 8946207 8221695 (more) 7640224 9315096 10101594 11505267 11564577 9562620 9703873 10748295 10943202 8058330 8634085 12747754 9916925 9563903 8527390 7739541 11376805 12640106 15024701 18204431
30	SSX3	SSX Family Member 3	Protein Coding	36.67	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Gene name Summaries Functions (show sections)
31	TFE3	Transcription Factor Binding To IGHM Enhancer 3	Protein Coding	36.54	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Disorders Publications Summaries (show sections)	18176180 11244503
32	SSX5	SSX Family Member 5	Protein Coding	36.22	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Gene name Summaries Functions (show sections)
33	SSX2B	SSX Family Member 2B	Protein Coding	33.53	GeneCards inferred via : Disorders Publications Gene name Summaries (show sections)
34	MDM2	MDM2 Proto-Oncogene	Protein Coding	33.33	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications Functions (show sections)	18521197 16160477 8064888 (more) 14614050 8946207 18922973 18500263 8221695 9627179 8306343 11921282 8387391 11307150 9057590 7591308 14612455 10412269 9071998 10606188 7828148 8117620 12574910 10803408 10101594 11494132 11564577 11742497 15024701 11376805 16930603 11148027 9278461 8781571 7477326 7923211 7519048 8219216 8350630 19820690 8064890 8261417 10942797 9891508 9861017 8797875 7803538 8066072 9569028 18521196 16818505 10943202 10631371 15647767 14723816 14707284 11213836 10737722 8750585 7738717 7946596 9769946 9159347 8943816 9172803 8527390 8288680 17369843 17536310 10748295 11956608 9528860 8199038 8324731 8479525 8630877 16022282 11393276 16478747 8821948 18204431 11958662 12640106 12652620 12917637
35	CDK6	Cyclin Dependent Kinase 6	Protein Coding	31.74	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications Proteins Pathways & Interactions (show sections)	17122635 8058330
36	ETV1	ETS Variant Transcription Factor 1	Protein Coding	31.62	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries (show sections)
37	FUS	FUS RNA Binding Protein	Protein Coding	31.04	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications Gene name (show sections)	18162764 12915480 10602519 (more) 20406182 18620564 15492825
38	CTNNB1	Catenin Beta 1	Protein Coding	30.95	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)
39	MOS	MOS Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	30.85	GeneCards inferred via : Publications Gene name Functions Domains & Families (show sections)
40	SSX4B	SSX Family Member 4B	Protein Coding	30.76	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Gene name Summaries (show sections)
41	IL6	Interleukin 6	Protein Coding	30.68	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)
42	CRK	CRK Proto-Oncogene, Adaptor Protein	Protein Coding	30.61	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications Gene name Functions (show sections)	19737974 17210721
43	RAF1	Raf-1 Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	29.91	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications Pathways & Interactions Functions (show sections)	18474006 8755507
44	FGR	FGR Proto-Oncogene, Src Family Tyrosine Kinase	Protein Coding	28.66	DISEASES inferred ¹⁵ GeneCards inferred via : Gene name Functions Domains & Families (show sections)
45	ROS1	ROS Proto-Oncogene 1, Receptor Tyrosine Kinase	Protein Coding	28.44	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Gene name Functions (show sections)
46	ATF1	Activating Transcription Factor 1	Protein Coding	28.26	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications Summaries (show sections)	12721254 9160316 17724745
47	SAGE1	Sarcoma Antigen 1	Protein Coding	28.01	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Gene name Proteins (show sections)
48	XAGE1B	X Antigen Family Member 1B	Protein Coding	27.98	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Summaries Expressions (show sections)
49	XAGE1A	X Antigen Family Member 1A	Protein Coding	27.96	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Summaries Expressions (show sections)
50	ICAM1	Intercellular Adhesion Molecule 1	Protein Coding	27.92	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Pathways & Interactions Functions (show sections)

Sources

Variations for Sarcoma

ClinVar genetic disease variations for Sarcoma:

⁶ (show all 16) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	GRCh37 Pos	GRCh38 Pos
1	CHEK2	NM_007194.4(CHEK2):c.341G>A (p.Trp114Ter)	SNV	Pathogenic	560005	rs1555927374	22:29121334-29121334	22:28725346-28725346
2	TP53	NM_000546.6(TP53):c.743G>A (p.Arg248Gln)	SNV	Pathogenic	12356	rs11540652	17:7577538-7577538	17:7674220-7674220
3	PIK3CA	NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys)	SNV	Pathogenic	13655	rs104886003	3:178936091-178936091	3:179218303-179218303
4	TP53	NM_001126112.2(TP53):c.886C>T (p.His296Tyr)	SNV	Uncertain significance	132973	rs672601296	17:7577052-7577052	17:7673734-7673734
5	TP53	NM_001126112.2(TP53):c.460G>A (p.Gly154Ser)	SNV	Uncertain significance	133284	rs137852789	17:7578470-7578470	17:7675152-7675152
6	APC	NM_000038.6(APC):c.449A>G (p.Lys150Arg)	SNV	Uncertain significance	141928	rs371085910	5:112111352-112111352	5:112775655-112775655
7	TP53	NM_001126112.2(TP53):c.969G>A (p.Leu323=)	SNV	Likely benign	132974	rs672601297	17:7576877-7576877	17:7673559-7673559
8	TP53	NM_001126112.2(TP53):c.448_459del (p.Thr150_Pro153del)	deletion	not provided	133282	rs137852790	17:7578471-7578482	17:7675153-7675164
9	TP53	NM_001126112.2(TP53):c.450_459del (p.Pro151fs)	deletion	not provided	133283	rs137852791	17:7578471-7578480	17:7675153-7675162
10	FGFR3	NM_001163213.1(FGFR3):c.1893C>T (p.Asn631=)	SNV	not provided	132957	rs104886004	4:1807828-1807828	4:1806101-1806101
11	FGFR3	NM_001163213.1(FGFR3):c.1914C>G (p.Phe638Leu)	SNV	not provided	132958	rs104886005	4:1807849-1807849	4:1806122-1806122
12	FGFR3	NM_001163213.1(FGFR3):c.1941C>T (p.Leu647=)	SNV	not provided	132959	rs104886006	4:1807876-1807876	4:1806149-1806149
13	PIK3CA	NM_006218.2:c.1821+51A>T	SNV	not provided	132966
14	FGFR3	NM_001163213.1(FGFR3):c.2141G>A (p.Arg714His)	SNV	not provided	132968	rs104886024	4:1808377-1808377	4:1806650-1806650
15	KRAS	NM_033360.4(KRAS):c.216G>A (p.Met72Ile)	SNV	not provided	132970	rs104886028	12:25380242-25380242	12:25227308-25227308
16	KRAS	NM_033360.4(KRAS):c.219G>A (p.Arg73=)	SNV	not provided	132971	rs104886027	12:25380239-25380239	12:25227305-25227305

Sources

Expression for Sarcoma

Search GEO for disease gene expression data for Sarcoma.

Sources

Pathways for Sarcoma

Pathways related to Sarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 157)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶³ Show member pathways ILK Signaling ⁶³ MAPK Signaling ⁶³ Molecular Mechanisms of Cancer ⁶³ Rho Family GTPases ⁶³	13.94	TP53 SRC RB1 KRAS KIT JUN
2	GPCR Pathway ⁶³ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶³ Estrogen Pathway ⁶³ NFAT in Immune Response ⁶³ P2Y Receptor Signaling ⁶³ Pancreatic Adenocarcinoma ⁶³ Paxillin Interactions ⁶³ Ras Pathway ⁶³	13.82	TP53 SRC RB1 LYN KRAS KIT
3	TGF-Beta Pathway ⁶³ Show member pathways JAK-STAT Pathway ⁶³ JNK Pathway ⁶³ MAPK Family Pathway ⁶³ Regulation of eIF4 and p70S6K ⁶³ SOCS Pathway ⁶³	13.65	TP53 SRC PIK3CA KRAS KIT JUN
4	Developmental Biology ⁶⁵ Show member pathways Axon guidance ⁶⁵	13.63	SRC PIK3CA LYN KRAS KIT JUN
5	Cytokine Signaling in Immune system ⁶⁵ Show member pathways Signaling by Interleukins ⁶⁵	13.49	TP53 SRC PIK3CA LYN KRAS KIT
6	IL-2 Pathway ⁶³ Show member pathways ErbB Family Pathway ⁶³ ErbB2-ErbB3 Heterodimers ⁶³ ErbB4 Pathway ⁶³ Growth Hormone Signaling ⁶³ HMGB1 Pathway ⁶³ IL-4 Pathway ⁶³ LPS Stimulated MAPK Signaling ⁶³ PACAP Signaling ⁶³ PI3K Signaling in B-Lymphocyte ⁶³ Prolactin Signaling ⁶³ Thrombopoietin Pathway ⁶³ TREM1 Pathway ⁶³ UVC-Induced MAPK Signaling ⁶³	13.34	TP53 SRC LYN KRAS JUN HRAS
7	TNFR1 Pathway ⁶³ Show member pathways Apoptosis and survival TNFR1 signaling pathway ²² Apoptosis through Death Receptors ⁶³ Apoptotic Pathways Triggered By HIV1 ⁶³ Death Receptor Signaling ⁶⁶ DR3 Signaling ⁶³ Fas Signaling ⁶³ GITR Pathway ⁶³ HIV-1 Nef- Negative effector of Fas and TNF-alpha ¹ Stimulation of the cell death response by PAK-2p34 ⁶⁵ TNF alpha Signaling Pathway ¹ TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway ¹ TNF Signaling ⁶³ TNF Signaling ⁶⁶ TRAIL Pathway ⁶³ TWEAK Pathway ⁶³	13.2	TP53 SRC RB1 PIK3CA KRAS JUN
8	Phospholipase-C Pathway ⁶³ Show member pathways PTEN Pathway ⁶³	13.2	TP53 SRC LYN KRAS KIT HRAS
9	Toll-like Receptor Signaling Pathway ³⁶ ¹ Show member pathways Chagas disease (American trypanosomiasis) ³⁶ Hepatitis B ³⁶ Hepatitis C ³⁶ Regulation of toll-like receptor signaling pathway ¹	13.18	TP53 SRC RB1 PIK3CA KRAS JUN
10	fMLP Pathway ⁶³ Show member pathways Alpha-Adrenergic Signaling ⁶³ CCR3 Pathway in Eosinophils ⁶³ CXCR4 Pathway ⁶³ Huntington's Disease Pathway ⁶³ Internalin Pathway ⁶³ Signal transduction Activation of PKC via G-Protein coupled receptor ²² VEGF and S-1P Signaling ⁶³	13.12	TP53 SRC KRAS JUN HRAS BRAF
11	PI3K-Akt signaling pathway ³⁶ Show member pathways Human papillomavirus infection ³⁶	13.11	TP53 RB1 PIK3CA KRAS KIT HRAS
12	TCR Signaling (Qiagen) ⁶³ Show member pathways ITK and TCR Signaling ⁶³ PDGF Pathway ⁶³ PKC-Theta Pathway ⁶³ TCR Signaling ⁶³	13.06	TP53 SRC LYN KRAS JUN HRAS
13	Focal Adhesion ³⁶ ¹ Show member pathways HGF Pathway ⁶³ Integrin-mediated Cell Adhesion ¹	13.04	SRC RB1 PIK3CA KRAS JUN HRAS
14	Regulation of lipid metabolism Insulin signaling-generic cascades ²² Show member pathways acetyl-CoA biosynthesis from citrate ¹ Butyrate-induced histone acetylation ¹ Cell adhesion PLAU signaling ²² Class IB PI3K non-lipid kinase events ¹ Development CNTF receptor signaling ²² Development Growth hormone signaling via PI3K/AKT and MAPK cascades ²² ErbB2/ErbB3 signaling events ¹ Glucose Homeostasis ¹ Insulin signaling pathway ³⁶ IRS activation ⁶⁵ Signal attenuation ⁶⁵ Transcription Receptor-mediated HIF regulation ²² Translation Regulation of EIF2 activity ²² Translation Regulation of EIF4F activity ²² Translation Insulin regulation of translation ²²	13.03	SRC PIK3CA KRAS JUN HRAS BRAF
15	Human cytomegalovirus infection ³⁶ Show member pathways Human immunodeficiency virus 1 infection ³⁶ Kaposi sarcoma-associated herpesvirus infection ³⁶	13.03	TP53 SRC RB1 PIK3CA LYN KRAS
16	MAPK Erk Pathway ⁶⁶ Show member pathways Actin Dynamics Signaling Pathway ⁶⁶ G Protein coupled Receptors Signaling ⁶⁶	13.01	SRC PIK3CA LYN KRAS HRAS BRAF
17	CCR5 Pathway in Macrophages ⁶³ Show member pathways Androgen Signaling ⁶³ Chemokine Signaling ⁶³ Chemokine signaling pathway ³⁶	13.01	SRC PIK3CA LYN KRAS JUN HRAS
18	NFAT and Cardiac Hypertrophy ⁶³ Show member pathways IGF1R Signaling ⁶³ Signaling Involved in Cardiac Hypertrophy ⁶³	12.99	SRC PIK3CA KRAS JUN HRAS BRAF
19	Pathways in cancer ³⁶	12.93	TP53 RB1 PIK3CA KRAS KIT JUN
20	Measles ³⁶ Show member pathways Epstein-Barr virus infection ³⁶ Influenza A ³⁶	12.92	TP53 RB1 PIK3CA LYN JUN
21	Beta-Adrenergic Signaling ⁶³ Show member pathways CDK5 Pathway ⁶³ Erythropoietin Pathway ⁶³ Insulin Receptor Pathway ⁶³	12.91	SRC KRAS JUN HRAS BRAF
22	MAPK signaling pathway ³⁶ ¹	12.9	TP53 KRAS KIT JUN HRAS BRAF
23	Common Cytokine Receptor Gamma-Chain Family Signaling Pathways ⁶⁴ Show member pathways Adipocytokines and Insulin Signaling ⁶⁴ Development Thrombopoietin-regulated cell processes ²² IL-15 Signaling Pathways ⁶⁴ IL-2 Signaling Pathways ⁶⁴ IL-21 Signaling Pathways ⁶⁴ IL-4 Signaling Pathways ⁶⁴ IL-7 Signaling Pathways ⁶⁴ IL-9 Pathway ⁶³ IL-9 Signaling Pathways ⁶⁴ Immune response IL-9 signaling pathway ²²	12.88	PIK3CA KRAS JUN HRAS BRAF
24	Ras signaling pathway ³⁶ Show member pathways Rap1 signaling pathway ³⁶	12.87	SRC PIK3CA KRAS KIT HRAS BRAF
25	Development Angiotensin activation of ERK ²² Show member pathways Cell adhesion Integrin inside-out signaling ²² Development ACM2 and ACM4 activation of ERK ²² Development Angiotensin signaling via PYK2 ²² Development EDNRB signaling ²² Development EPO-induced MAPK pathway ²² Development G-Proteins mediated regulation MARK-ERK signaling ²² Signal transduction IP3 signaling ²²	12.84	SRC PIK3CA LYN KRAS KIT JUN
26	Apoptosis Modulation and Signaling ¹ Show member pathways Apoptosis ³⁶ Apoptosis ¹ Apoptosis and survival Apoptotic TNF-family pathways ²² Apoptosis Signaling Pathways ⁶⁴	12.83	TP53 PIK3CA KRAS JUN HRAS
27	Downstream signaling events of B Cell Receptor (BCR) ⁶⁵ Show member pathways Activation of RAS in B cells ⁶⁵ Signaling by the B Cell Receptor (BCR) ⁶⁵	12.83	TP53 SRC PIK3CA LYN KRAS KIT
28	4-1BB Pathway ⁶³ Show member pathways CD27 Pathway ⁶³ CD40 Signaling ⁶³ CMV and MAPK Pathways ⁶³ NF-KappaB Activation by EBV ⁶³ NF-kappaB Activation by Viruses ⁶³ PKR Pathway ⁶³ SUMO Pathway ⁶³ TNFR2 Pathway ⁶³	12.81	TP53 RB1 KRAS JUN HRAS BRAF
29	Development HGF signaling pathway ²² Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development Neurotrophin family signaling ²² MET activates PTPN11 ⁶⁵ MET activates STAT3 ⁶⁵ Neurotrophin signaling pathway ³⁶ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	12.81	TP53 SRC PIK3CA KRAS JUN HRAS
30	Relaxin signaling pathway ³⁶ Show member pathways Estrogen signaling pathway ³⁶ Growth hormone synthesis, secretion and action ³⁶ Relaxin receptors ⁶⁵	12.8	SRC PIK3CA KRAS JUN HRAS
31	nNOS Signaling in Skeletal Muscle ⁶³ Show member pathways BMP Pathway ⁶³ Calpain Protease Regulates Cellular Mechanics ⁶³ Caspase Cascade ⁶³ Depolarization of the Presynaptic Terminal Triggers the Opening of Calcium Channels ⁶⁵ DREAM Repression and Dynorphin Expression ⁶³ TOB in Osteoblast Signaling ⁶³	12.8	SRC RB1 KRAS JUN HRAS
32	Gastric cancer ³⁶ Show member pathways Breast cancer ³⁶ Hepatocellular carcinoma ³⁶	12.8	TP53 RB1 PIK3CA KRAS KIT JUN
33	Endometrial cancer ³⁶ Show member pathways Acute myeloid leukemia ³⁶ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁵ Chronic myeloid leukemia ³⁶ Colorectal cancer ³⁶ Pancreatic cancer ³⁶ Prostate cancer ³⁶ Signal transduction PTEN pathway ²² Thyroid cancer ³⁶	12.8	TP53 SRC RB1 PIK3CA KRAS KIT
34	Development Endothelin-1/EDNRA signaling ²² Show member pathways Cytoskeleton remodeling FAK signaling ²² Development Endothelin-1/EDNRA transactivation of EGFR ²² GnRH signaling pathway ³⁶ Inflammatory mediator regulation of TRP channels ³⁶	12.77	SRC PIK3CA KRAS JUN HRAS
35	Regulation of actin cytoskeleton ³⁶ ¹	12.76	SRC PIK3CA KRAS HRAS BRAF
36	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶³ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²² Rac1/Pak1/p38/MMP-2 pathway ¹	12.73	TP53 SRC PIK3CA KRAS HRAS FES
37	Immune response Fc epsilon RI pathway ²² Show member pathways Fc epsilon RI signaling pathway ³⁶ Fc-epsilon receptor I signaling in mast cells ¹ Immune response BCR pathway ²² VEGF signaling pathway ³⁶	12.73	SRC PIK3CA LYN KRAS JUN HRAS
38	ErbB signaling pathway ³⁶ ¹ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰

Sarcoma

Aliases & Classifications for Sarcoma

MalaCards integrated aliases for Sarcoma:

Classifications:

External Ids:

Summaries for Sarcoma

Related Diseases for Sarcoma

Diseases related to Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Sarcoma:

Symptoms & Phenotypes for Sarcoma

GenomeRNAi Phenotypes related to Sarcoma according to GeneCards Suite gene sharing:

MGI Mouse Phenotypes related to Sarcoma:

Drugs & Therapeutics for Sarcoma

Drugs for Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Genetic Tests for Sarcoma

Genetic tests related to Sarcoma:

Anatomical Context for Sarcoma

MalaCards organs/tissues related to Sarcoma:

Publications for Sarcoma

Articles related to Sarcoma:

Genes for Sarcoma

Genes related to Sarcoma (3 elite genes):

Variations for Sarcoma

ClinVar genetic disease variations for Sarcoma:

Expression for Sarcoma

Pathways for Sarcoma

Pathways related to Sarcoma according to GeneCards Suite gene sharing:

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :